Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC
出版年份 2019 全文链接
标题
Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC
作者
关键词
Non-small cell lung cancer, Chemoradiotherapy, Anti-PD-1 therapy
出版物
International Journal of Clinical Oncology
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-09-11
DOI
10.1007/s10147-019-01537-4
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Real-world outcomes in patients with unresected stage III non-small cell lung cancer
- (2019) Kellie J. Ryan et al. MEDICAL ONCOLOGY
- Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
- (2019) Howard West et al. LANCET ONCOLOGY
- Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995–2017
- (2019) Natsuki Takano et al. LUNG CANCER
- Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer
- (2018) Neal S. McCall et al. CLINICAL CANCER RESEARCH
- IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.
- (2018) Robert M. Jotte et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
- (2017) Narek Shaverdian et al. LANCET ONCOLOGY
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of Local Radiation Therapy in Cancer Immunotherapy
- (2015) Sandra Demaria et al. JAMA Oncology
- Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
- (2014) S. J. Dovedi et al. CANCER RESEARCH
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
- (2014) Liufu Deng et al. JOURNAL OF CLINICAL INVESTIGATION
- Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
- (2010) Anne Aupérin et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started